文献速递肿瘤 PET/CT

89Zr标记amivantamab双特异性抗体用于三阴性乳腺癌PET显像的临床前开发

Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-08-08

本研究将靶向EGFR和c-MET的双特异性抗体amivantamab与去铁胺偶联并标记89Zr,在多种三阴性乳腺癌(TNBC)异种移植模型中评估其药理学与显像特性。结果显示[89Zr]ZrDFO-amivantamab在共表达EGFR和c-MET的肿瘤中摄取最高,PET/CT的SUVmean与受体表达水平一致,提示其有潜力作为amivantamab治疗的伴随诊断显像剂。

要点

  • 成功制备[89Zr]ZrDFO-amivantamab,比活度为148 MBq/mg,放射化学产率≥95%。
  • TNBC异种移植瘤PET/CT的SUVmean:MDA-MB-468为6.0±1.1,MDA-MB-231为4.2±1.4,MDA-MB-453为1.5±1.4。
  • 肿瘤摄取与EGFR和c-MET表达水平一致,共表达者摄取最高。

核心结论

  • 成功制备放射性标记的双特异性抗体[89Zr]ZrDFO-amivantamab并在TNBC临床前模型中验证其药理学和显像特性。
  • [89Zr]ZrDFO-amivantamab在共表达EGFR和c-MET的肿瘤中显示出最高摄取。

研究设计与样本

  • 临床前研究:将amivantamab与去铁胺(DFO)偶联并用89Zr标记,在体外和体内比较双特异性抗体与单臂抗体对照的结合。
  • 在MDA-MB-468异种移植瘤中进行生物分布研究以确定最佳显像时间点。
  • 在一组EGFR和c-MET表达水平不同的TNBC异种移植瘤中进行[89Zr]ZrDFO-amivantamab或其同型对照的PET/CT显像。

主要发现

  • [89Zr]ZrDFO-amivantamab的比活度为148 MBq/mg,放射化学产率≥95%。
  • 放射配体结合实验和western blot确认EGFR和c-MET表达水平顺序:HCC827肺癌细胞(阳性对照)> MDA-MB-468 > MDA-MB-231 > MDA-MB-453。
  • [89Zr]ZrDFO-amivantamab在共表达EGFR和c-MET的细胞系中显示双特异性结合。
  • TNBC异种移植小鼠PET/CT的SUVmean:MDA-MB-468为6.0±1.1,MDA-MB-231为4.2±1.4,MDA-MB-453为1.5±1.4,与细胞表面受体表达水平一致。

临床怎么用

  • 本研究为临床前开发阶段,[89Zr]ZrDFO-amivantamab有潜力作为amivantamab治疗的伴随诊断显像剂,尚需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Amivantamab is a novel bispecific antibody that simultaneously targets the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (HGFR/c-MET) that are overexpressed in several types of cancer including triple-negative breast cancer (TNBC). Targeting both receptors simultaneously can overcome resistance to mono-targeted therapy. The purpose of this study is to develop 89Zr-labeled amivantamab as a potential companion diagnostic imaging agent to amivantamab therapy using various preclinical models of TNBC for evaluation. METHODS: Amivantamab was conjugated to desferrioxamine (DFO) and radiolabeled with 89Zr to obtain [89Zr]ZrDFO-amivantamab. Binding of the bispecific [89Zr]ZrDFO-amivantamab as well as its mono-specific "single-arm" antibody controls were determined in vitro and in vivo. Biodistribution studies of [89Zr]ZrDFO-amivantamab were performed in MDA-MB-468 xenografts to determine the optimal imaging time point. PET/CT imaging with [89Zr]ZrDFO-amivantamab or its isotype control was performed in a panel of TNBC xenografts with varying levels of EGFR and c-MET expression. RESULTS: [89Zr]ZrDFO-amivantamab was synthesized with a specific activity of 148 MBq/mg and radiochemical yield of ≥ 95%. Radioligand binding studies and western blot confirmed the order of EGFR and c-MET expression levels: HCC827 lung cancer cell (positive control) > MDA-MB-468 > MDA-MB-231 > MDA-MB-453. [89Zr]ZrDFO-amivantamab demonstrated bispecific binding in cell lines co-expressed with EGFR and c-MET. PET/CT imaging with [89Zr]ZrDFO-amivantamab in TNBC xenografted mice showed standard uptake value (SUVmean) of 6.0 ± 1.1 in MDA-MB-468, 4.2 ± 1.4 in MDA-MB-231, and 1.5 ± 1.4 in MDA-MB-453 tumors, which are consistent with their receptors' expression levels on the cell surface. CONCLUSION: We have successfully prepared a radiolabeled bispecific antibody, [89Zr]ZrDFO-amivantamab, and evaluated its pharmacologic and imaging properties in comparison with its single-arm antibodies and non-specific isotype controls. [89Zr]ZrDFO-amivantamab demonstrated the greatest uptake in tumors co-expressing EGFR and c-MET.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cavaliere A, Sun S, Lee S, et al. Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 32770372. doi:10.1007/s00259-020-04978-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。